Teva Pharm Q2 profit beats estimates as branded drugs gain

Teva Pharmaceutical Industries reported a stronger-than-expected second-quarter profit of 66 cents per diluted share, ex-items, surpassing analyst forecasts of 62 cents, primarily driven by robust sales gains in its branded drug portfolio for migraines, Huntington's disease, and schizophrenia. While revenue remained flat at $4.18 billion, slightly below estimates, the company largely reaffirmed its 2025 financial outlook, with a slight upward revision to its adjusted EPS forecast range to $2.50-$2.65.

Analysis

Teva Pharmaceutical Industries (TEVA.TA) reported a notable second-quarter earnings beat, with adjusted EPS of $0.66 surpassing both the consensus estimate of $0.62 and the prior-year figure of $0.61. This outperformance in profitability was driven by strong sales gains in its branded drug portfolio, specifically treatments for migraines, Huntington's disease, and schizophrenia. This is a significant development as the strength in higher-margin branded products offset a weaker top-line performance, where revenue remained flat at $4.18 billion, missing the forecast of $4.28 billion. Looking forward, the company's management signaled confidence by reaffirming its 2025 estimates and slightly raising its adjusted EPS forecast to a new range of $2.50-$2.65, suggesting an optimistic outlook on continued profitability.

Key Decisions for Investors

• Investors should assess the fundamental shift in Teva's profit drivers, focusing on the growth and margin contribution from the branded drug portfolio as it appears to be compensating for weakness in the broader generics business.
• While the earnings beat is positive, the revenue miss warrants attention; it is prudent to monitor future top-line growth to validate that the current profit expansion is sustainable.
• The upward revision to the 2025 adjusted EPS guidance serves as a key performance indicator, and the company's ability to meet or exceed this new range will be critical for investor confidence.